Clinical Trial Update: A Randomized, Double-blind, Placebo-controlled, Sequential Ascending, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2212 in Healthy Subjects [Phase 1]

View source ↗

Summary

This is a Phase 1 randomized, double-blind, placebo-controlled, sequential ascending, single-dose study by Eisai Inc. to evaluate the safety, tolerability, phar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• E2212

Snippet

Sponsor: Eisai Inc. | Conditions: Alzheimer's Disease | Phase 1 | Status: COMPLETED